Verici Dx (LON:VRCI) Trading 15.3% Higher

Shares of Verici Dx plc (LON:VRCIGet Free Report) traded up 15.3% on Monday . The stock traded as high as GBX 6.98 ($0.09) and last traded at GBX 6.98 ($0.09). 179,121 shares changed hands during mid-day trading, a decline of 49% from the average session volume of 354,601 shares. The stock had previously closed at GBX 6.05 ($0.08).

Verici Dx Stock Up 15.3 %

The firm has a market cap of £16.92 million, a price-to-earnings ratio of -125.00 and a beta of 1.53. The firm’s 50 day moving average price is GBX 7.40 and its two-hundred day moving average price is GBX 8.74. The company has a debt-to-equity ratio of 9.28, a current ratio of 2.58 and a quick ratio of 8.49.

Verici Dx Company Profile

(Get Free Report)

Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its lead products comprise Tutivia, a post-transplant test focused on acute rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.

Featured Articles

Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.